Publication | Closed Access

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial

PsychoneuroimmunologyPsychiatrySystemic TreatmentClinical TrialsDepressionClinical DermatologyDermatologyExperimental DermatologySkin-related QualityMedicineModerate-to-severe Psoriasis